Figure 7.The relationship between the risk assessment model and common targeted drugs, including axitinib (A), bosutinib (B), imatinib (C), pazopanib (D), rapamycin (E), sorafenib (F), sunitinib (G), temsirolimus (H).
Figure 7 — A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC | Aging
